Drug Profile
Research programme: cell therapy - Angiocrine Bioscience
Alternative Names: E-CEL PEC™; E-CEL TEC™Latest Information Update: 21 Sep 2023
Price :
$50
*
At a glance
- Originator Angiocrine Bioscience
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Lung disorders; Tendon injuries
Most Recent Events
- 21 Sep 2023 Discontinued - Preclinical for Lung disorders in USA (Parenteral)
- 21 Sep 2023 Discontinued - Preclinical for Tendon injuries in USA (Parenteral)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Lung-disorders in USA (Parenteral)